| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Prostate Nerve Reconstruction Investor Event November 9, 2026 |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – October 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busi... |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair |
| 10 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Axogen, Inc., a Minnesota corporation (the “Company”) confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Jefferies LLC (“Jefferies”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters name... |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – July 29, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busines... |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 23, 2026, Axogen, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”), at which a total of 45,364,808 shares of common stock of the Company, out of a total 53,177,824 shares of common stock ou... |
| 28 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – April 28, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busine... |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – February 24, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and bus... |
| 23 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Axogen, Inc., a Minnesota corporation (the “Company”) confirms its agreement with Wells Fargo Securities, LLC (“Wells Fargo”) and Mizuho Securities USA LLC (“Mizuho”) and each of the other Underwriters named in Schedule A hereto (collect... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
1 Making Nerve Repair an Expected Standard of Care A commitment to restoring health, improving quality of life, and advancing peripheral nerve care for every patient. Michael Dale, President & CEO January 2026 |
| 05 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This Amended and Restated Confidentiality, Intellectual Property, Non-Competition and Non-Solicitation Agreement (this “Amended Amended IP and NCNS Agreement”) is effective as of December 5, 2025 (the “Effective Date”) by and between Axo... |
| 04 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
ALACHUA, FL and TAMPA, FL – December 3, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food... |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – October 29, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busi... |
| 25 Aug 2025 |
8-K: Regulation FD Disclosure
ALACHUA, FL and TAMPA, FL – August 25, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the U.S. Food and... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – August 5, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and busine... |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2025, Axogen, Inc. (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”), at which a total of 37,190,480 shares of common stock of the Company, out of a total 45,534,866 shares of common stock ou... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), effective as of May 12, 2025 (the “Effective Date”), is made by and between AXOGEN CORPORATION, a Delaware corporation (“AXOGEN”), and Lindsey Hartley (“Employee”) (collectively, the... |
| 07 Apr 2025 |
8-K: Regulation FD Disclosure
On April 2, 2025, President Donald J. Trump announced a plan that would implement a broad range of tariffs on goods imported into the United States. Axogen, Inc. (the "Company") anticipates minimal impact from these tariffs, as well as f... |
| 04 Mar 2025 |
8-K: Regulation FD Disclosure
The Standard of Nerve Care Investor Presentation March 4th, 2025 1 |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ALACHUA and TAMPA, FL – February 25, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights fo... |
Loading...